Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
12.86
-0.27 (-2.06%)
At close: Aug 24, 2026, 4:00 PM EDT
13.24
+0.38 (2.95%)
Pre-market: Aug 25, 2026, 8:24 AM EDT
Candel Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 201.57 | 119.73 | 102.65 | 35.41 | 70.06 | 82.64 |
Cash & Short-Term Investments | 201.57 | 119.73 | 102.65 | 35.41 | 70.06 | 82.64 |
Cash Growth | 100.19% | 16.63% | 189.88% | -49.45% | -15.23% | 135.76% |
Prepaid Expenses | 2.59 | 1.66 | 1.15 | 1.38 | 1.89 | 2.3 |
Total Current Assets | 204.16 | 121.39 | 103.8 | 36.8 | 71.95 | 84.95 |
Property, Plant & Equipment | 3.48 | 3.3 | 2.73 | 4.02 | 5.48 | 3.84 |
Other Long-Term Assets | 0.51 | 0.5 | 0.33 | 0.38 | 0.27 | 0.42 |
Total Assets | 208.15 | 125.2 | 106.87 | 41.2 | 77.69 | 89.21 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.15 | 1.13 | 0.24 | 0.42 | 0.38 | 1.59 |
Accrued Expenses | 6.52 | 6.87 | 4.72 | 3.96 | 4.72 | 3.44 |
Current Portion of Long-Term Debt | - | - | 9.9 | 8.89 | - | - |
Current Portion of Leases | 0.46 | 0.45 | 0.57 | 0.51 | 0.46 | - |
Other Current Liabilities | 0.56 | 0.55 | 22.11 | 0.4 | 0.05 | 0.33 |
Total Current Liabilities | 12.69 | 9 | 37.53 | 14.18 | 5.62 | 5.36 |
Long-Term Debt | 47.83 | 47.13 | 2.6 | 12.38 | 20.85 | 0.56 |
Long-Term Leases | 1.23 | 1.46 | 0.41 | 0.97 | 1.49 | - |
Long-Term Unearned Revenue | 0.05 | 0.09 | - | - | 0.14 | - |
Other Long-Term Liabilities | 20.23 | 15.6 | - | 0.92 | 1.88 | 19.15 |
Total Liabilities | 82.02 | 73.27 | 40.54 | 28.46 | 29.98 | 25.07 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.76 | 0.55 | 0.47 | 0.29 | 0.29 | 0.29 |
Additional Paid-In Capital | 403.97 | 282.21 | 258.51 | 149.93 | 146.96 | 144.15 |
Retained Earnings | -278.15 | -230.39 | -192.21 | -137.03 | -99.09 | -80.3 |
Treasury Stock | -0.45 | -0.45 | -0.45 | -0.45 | -0.45 | - |
Total Common Equity | 126.13 | 51.92 | 66.33 | 12.75 | 47.71 | 64.14 |
Shareholders' Equity | 126.13 | 51.92 | 66.33 | 12.75 | 47.71 | 64.14 |
Total Liabilities & Equity | 208.15 | 125.2 | 106.87 | 41.2 | 77.69 | 89.21 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 49.52 | 49.03 | 13.47 | 22.76 | 22.8 | 0.56 |
Net Cash (Debt) | 152.05 | 70.7 | 89.18 | 12.65 | 47.26 | 82.08 |
Net Cash Growth | 64.65% | -20.73% | 604.95% | -73.23% | -42.43% | 140.66% |
Net Cash Per Share | 2.47 | 1.33 | 2.82 | 0.44 | 1.64 | 4.35 |
Filing Date Shares Outstanding | 76.52 | 73.25 | 47.24 | 29.35 | 28.92 | 28.69 |
Total Common Shares Outstanding | 76.12 | 54.9 | 46.81 | 29.09 | 28.92 | 28.69 |
Working Capital | 191.47 | 112.39 | 66.28 | 22.61 | 66.33 | 79.58 |
Book Value Per Share | 1.66 | 0.95 | 1.42 | 0.44 | 1.65 | 2.24 |
Tangible Book Value | 126.13 | 51.92 | 66.33 | 12.75 | 47.71 | 64.14 |
Tangible Book Value Per Share | 1.66 | 0.95 | 1.42 | 0.44 | 1.65 | 2.24 |
Machinery | 2.87 | 2.19 | 2.16 | 2.19 | 2.5 | 1.19 |
Leasehold Improvements | 3.01 | 3.01 | 3.11 | 3.11 | 3.06 | 2.99 |